IPO
NOXXON Pharma N.V., announced its decision to suspend trading on Friday, December 14, 2018.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
Potential upside of more than 42% compared to MAB closing price of EUR 1.66 on 10 December 2018
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
The long-awaited and massively hyped initial public offering of Moderna Therapeutics hit the market yesterday. The company sold approximately 26.3 million shares priced at $23 a share. This exceeded the revised goal of $600 million by about $4.3 million.
TESARO, Inc. today announced that, pursuant to the terms of the indenture (the “Indenture”) governing the terms of its 3.00% Convertible Senior notes due 2021
Moderna Therapeutics raised some eyebrows last week when it refiled with the Securities and Exchange Commission (SEC), raising its goal for its initial public offering from $500 million to $600 million. The company, which has no products on the market, is fantastic at raising money, but some analysts wonder if the company is overvalued.
The Cambridge, Mass.-based biotech company, which had proposed a $500 million initial public offering (IPO) earlier this month, came back Wednesday with a new goal of $600 million.
Galapagos NV announces a share capital increase arising from warrant exercises.
Thomas Eldered, CEO and co-founder of Recipharm AB, has informed the Company that he has sold 1,559,125 Class B shares in Recipharm, representing approximately 12.7% of his total shareholding in the Company, to a Swedish institutional investor.
PRESS RELEASES